Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.940
+0.090 (1.86%)
Oct 7, 2026, 10:37 AM EDT - Market open
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,002,393
Profits / Employee
-$2,708,703
Market Cap
115.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - |
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | 2 | 33.33% |
| Dec 31, 2022 | 6 | 0 | - |
| Sep 30, 2022 | 6 | 0 | - |
| Jun 30, 2022 | 6 | - | - |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Seer, Inc. | 124 |
| Cibus | 118 |
| Inovio Pharmaceuticals | 112 |
| Foghorn Therapeutics | 106 |
| enGene Therapeutics | 82 |
| Corbus Pharmaceuticals Holdings | 36 |
| Genelux | 26 |
COYA News
- 2 days ago - Coya announces full enrollment in Phase 2/3 ALSTARs trial of COYA 302 - TheFly
- 2 days ago - Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
- 22 days ago - Coya Therapeutics announces 100th patient enrolled in Phase 2/3 ALSTARS trial - TheFly
- 22 days ago - Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
- 4 weeks ago - Coya announces publication of preclinical study on effects of COYA 303 - TheFly
- 4 weeks ago - Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation - Business Wire
- 5 weeks ago - Coya Therapeutics Slides: Investor presentation - Filings
- 1 month ago - Coya Therapeutics reports Q2 EPS (28c), consensus (36c) - TheFly